Orlistat’s most common side effects are gastrointestinal: oily or fatty stools, loose bowel movements, abdominal pain, gas with oily discharge, and fecal spotting. These effects are not rare complications but a direct consequence of how the drug works, which is by blocking the digestion of roughly a third of the fat you eat and sending it through your system unabsorbed. The gut-related symptoms are so predictable that they show up in the majority of users during the first weeks and months, and they are the leading reason people stop taking the drug. But orlistat’s side-effect profile extends beyond the bathroom, reaching into vitamin absorption, kidney health, and a handful of other areas that get far less attention.
Why the Side Effects Are Built Into the Mechanism
Orlistat works by blocking lipase enzymes in the stomach and small intestine, the enzymes responsible for breaking dietary fat into smaller molecules your body can absorb.1PubMed. Mode of action of orlistat When those enzymes are disabled, triglycerides from your meal pass through your digestive tract largely intact. Studies in healthy volunteers found that orlistat inhibits gastric lipase by anywhere from about 47% to over 91%, depending on the type of meal, and pancreatic lipase by roughly 51% to 83%.2PubMed. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers All that undigested fat has to go somewhere, and it exits in your stool. The enzyme inhibition starts within a minute of the drug reaching the stomach, which is why the gastrointestinal effects tend to show up early and often.
This also means the severity of the side effects is directly tied to how much fat you eat. A high-fat meal gives the unblocked fat nowhere to go except through your colon, producing the characteristic oily stools and urgency. A lower-fat meal leaves less undigested fat behind. Some people describe this as a built-in dietary enforcement mechanism: eat too much fat, and the drug will let you know.
The Gastrointestinal Effects in Detail
The list of common GI side effects reads like a catalogue of digestive discomfort. A critical review of orlistat’s safety profile identified oily stools, diarrhea, abdominal pain, and fecal spotting as the most consistently reported problems.3PubMed. Orlistat-associated adverse effects and drug interactions: a critical review A large prescription-monitoring study of over 15,000 patients in the UK found that diarrhea affected about 2.3% of users in the first month alone, along with flatulence, nausea, rectal discharge, and in some cases fecal incontinence.4Nature. Safety profile of orlistat: results of a prescription-event monitoring study In clinical trials involving adolescents, GI adverse events were reported in anywhere from 9% to 50% of the orlistat group, compared with 1% to 13% of the placebo group.5JAMA. Effect of Orlistat on Weight and Body Composition in Obese Adolescents: A Randomized Controlled Trial
These symptoms tend to be worst during the first few weeks and gradually ease. One study of orlistat use noted that fat-malabsorption-related side effects occurred in more than 20% of subjects during the first year but diminished in the second year. Part of that decline is genuine adaptation, but part of it is self-selection: people who cannot tolerate the effects simply stop taking the drug. A meta-analysis found that the risk of dropping out due to adverse events was about 59% higher with orlistat than with placebo, and GI complaints accounted for roughly 40% of those withdrawals.6PubMed. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis
Managing the Gut Symptoms
The most effective strategy for reducing orlistat’s GI effects is straightforward: keep your fat intake moderate. Most guidelines suggest spreading your daily fat across meals and aiming for no more than about 15 grams of fat per meal. If you eat a very low-fat meal, you can sometimes skip the dose entirely, since there is little fat for the drug to block. If you eat a greasy restaurant meal, the consequences tend to be swift and memorable.
Some users report that they learn to time their doses around meals with varying fat content, treating the drug almost as a flexible tool rather than a fixed three-times-daily regimen. Research bears this out: one study found that a large minority of users were taking orlistat flexibly as a “lifestyle drug” rather than following a strict dosing schedule.7PubMed Central. Taking Orlistat: Predicting Weight Loss over 6 Months Whether this flexible use preserves the drug’s effectiveness is another question, but it reflects how people actually cope with the side effects in daily life.
Fat-Soluble Vitamin Depletion
Because orlistat blocks fat absorption, it also interferes with the absorption of vitamins that dissolve in fat: vitamins A, D, E, and K. In a study of healthy volunteers, orlistat reduced vitamin E absorption by roughly 43% to 60%, though vitamin A absorption was not significantly affected at the doses tested.8PubMed. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers
Vitamin D appears to be the most clinically concerning deficiency. In a study of obese adolescents, vitamin D levels dropped significantly after just one month of orlistat use, even though the participants were taking a daily multivitamin.9PubMed. Effects of orlistat on fat-soluble vitamins in obese adolescents Vitamin K also showed a nonsignificant downward trend in the same study, which matters because vitamin K plays a role in blood clotting. The standard recommendation is to take a multivitamin at bedtime or at least two hours before or after your orlistat dose, so the vitamin and the fat-blocker are not competing in your gut at the same time. But even with supplementation, monitoring may be warranted, especially for vitamin D.
Kidney Risks and Oxalate Nephropathy
This is one of the lesser-known but more serious risks. When orlistat prevents fat from being absorbed, more free fatty acids reach the colon. These fatty acids bind to calcium, which leaves oxalate (a natural compound in many foods) free to be absorbed into the bloodstream. The kidneys then filter it out, and if oxalate levels get high enough, crystals can form in the kidney tissue itself.
Case reports describe patients who developed kidney failure from calcium oxalate deposits in their kidneys while taking orlistat.10PubMed Central. Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease In one case, acute kidney injury was linked temporally to an increased dose of orlistat and worsening fat malabsorption, confirmed by abundant oxalate crystals found in the urine and on kidney biopsy.11PubMed. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor The condition can develop insidiously and is easy to miss if clinicians are not looking for it.
In 2024, the FDA approved labeling changes for the over-the-counter version of orlistat (sold as Alli) to include a warning about acute kidney injury, after identifying 12 cases of kidney complications linked to OTC use between 2007 and 2023.12JAMA. FDA Adds Kidney Injury Warning to OTC Weight-Loss Drug Orlistat People with existing kidney disease, a history of kidney stones, or who eat diets high in oxalate-rich foods like spinach, rhubarb, and nuts may be at greater risk. Staying well hydrated and ensuring adequate calcium intake (which binds oxalate in the gut before it can be absorbed) are reasonable precautions.
The Liver Question
Liver injury has been a recurring concern with orlistat, enough that the FDA issued a warning about rare but severe liver damage. Published case reports include patients who developed subacute hepatitis that in rare instances progressed to liver failure requiring transplantation.13Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Liver Failure Requiring Transplantation After Orlistat Use
However, the largest study to examine this question, a self-controlled case series using UK medical records from nearly 95,000 orlistat users, found something surprising. The rate of liver injury was already elevated in the 90 days before patients started orlistat, and when the first 90 days of treatment were compared against that pre-treatment period, there was no additional increase in risk. When the analysis was restricted to definite cases of liver injury, there was no evidence of increased risk during treatment at all.14BMJ. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink The authors suggested that the apparent association between orlistat and liver injury may reflect the fact that people with early, undiagnosed liver problems (possibly related to obesity itself) are more likely to seek out weight-loss treatment. In other words, the obesity may be causing the liver injury, and the orlistat use just happens to coincide with it.
The practical takeaway is that idiosyncratic liver reactions to orlistat exist but appear to be genuinely rare. If you develop symptoms like unexplained itching, dark urine, yellowing of the skin, or upper-right abdominal pain while taking orlistat, you should stop the drug and see a doctor promptly.
Drug Interactions Worth Knowing About
Orlistat is not absorbed into the bloodstream in any meaningful amount, so it does not interact with most medications through the usual liver-metabolism pathways. A pharmacokinetic study testing orlistat alongside several commonly prescribed drugs found no significant interactions for almost every medication tested. The one clear exception was cyclosporine, an immunosuppressant used after organ transplants and for certain autoimmune conditions: orlistat reduced cyclosporine absorption by roughly a third.15The Journal of Clinical Pharmacology. Pharmacokinetic Evaluation of the Possible Interaction between Selected Concomitant Medications and Orlistat at Steady State in Healthy Subjects For someone whose transplant depends on maintaining stable cyclosporine levels, that is a dangerous drop.
Beyond cyclosporine, the fat-malabsorption effect can theoretically reduce the absorption of any fat-soluble medication taken at the same time. Levothyroxine (thyroid hormone replacement) is a commonly cited concern: there are case reports of patients needing higher thyroid hormone doses after starting orlistat. Anticoagulants like warfarin, which depend on vitamin K levels that orlistat can lower, may also be affected. Anyone on these medications should discuss timing and monitoring with their prescriber.
Gallbladder Effects
Rapid weight loss from any cause increases the risk of gallstones, and the question with orlistat is whether the drug itself adds an independent risk by changing how the gallbladder works. One study found that orlistat at the standard dose increased fasting gallbladder volume by about 47% and reduced gallbladder emptying by about 53% after one month. The hormone that signals the gallbladder to contract (cholecystokinin) was also suppressed. A persistent but milder version of this effect remained after a year.16PubMed. Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity A sluggish gallbladder that does not empty well creates conditions favorable for stone formation.
An earlier crossover study, however, found that a single dose of orlistat did not significantly reduce gallbladder contraction or cholecystokinin release after meals with varying fat content, suggesting the effect may build up over time rather than occurring immediately.17PubMed. Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study In the longer-term study, gallstones developed in 3 out of 40 patients, two of whom were on placebo with major weight loss. The numbers are too small to draw firm conclusions, but the mechanism is plausible enough that gallbladder discomfort or pain during orlistat use warrants medical evaluation.
Orlistat in Adolescents
Orlistat is the only weight-loss medication that has been approved by the FDA for use in adolescents aged 12 and older.18PubMed Central. Pharmacologic treatment of pediatric obesity In a randomized trial, adolescents taking orlistat saw their BMI decrease by 0.55 over the study period, while the placebo group’s BMI increased. The trade-off was that GI side effects hit 9% to 50% of the orlistat group compared with 1% to 13% on placebo.19JAMA. Effect of Orlistat on Weight and Body Composition in Obese Adolescents: A Randomized Controlled Trial
A systematic review and meta-analysis of anti-obesity drugs in young people found that orlistat combined with behavioral support reduced BMI by about 0.83 kg/m² compared with placebo, a modest effect, and came with a high prevalence of GI adverse effects.20PubMed. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis The vitamin D findings mentioned earlier came from adolescent subjects, which raises particular concern for a population that is still building bone mass. If orlistat is used in teenagers, vitamin monitoring and supplementation are not optional extras.
Effects on the Gut Microbiome
When a drug floods your colon with undigested fat, the bacterial community living there is bound to notice. Research on this front is still early, but initial studies are suggestive. One study found that after eight weeks of orlistat, some subjects showed a shift in the balance of major bacterial groups in the gut, with a decrease in one dominant phylum and an increase in another. Levels of certain beneficial bacteria, including Lactobacillus species, rose significantly.21PubMed. Impact of the lipase inhibitor orlistat on the human gut microbiota The researchers suggested that orlistat may reshape gut bacteria composition and affect the body through fatty acid metabolites produced by those altered bacteria.
An experimental study in healthy volunteers, however, found that orlistat-induced fat malabsorption mainly affected bacterial populations that were present in very low abundance (less than 0.01% of the total), and that short-chain fatty acids, the metabolic products gut bacteria generate that influence immune function and colon health, remained largely unchanged.22PubMed Central. Impact of Dietary Lipids on Colonic Function and Microbiota: An Experimental Approach Involving Orlistat-Induced Fat Malabsorption in Human Volunteers The evidence so far is conflicting and comes from small studies. Whether orlistat’s microbiome effects have any meaningful long-term health consequences is genuinely unknown at this point.
Metabolic Benefits That Offset Some Risk
Not everything on orlistat’s ledger is a side effect in the negative sense. Beyond weight loss itself, orlistat has been shown to reduce total cholesterol and LDL (“bad”) cholesterol levels and improve the ratio of LDL to HDL cholesterol, as well as reduce triglycerides after meals.23PubMed. The effects of orlistat on metabolic parameters and other cardiovascular risk factors Some of these improvements are partly independent of the weight loss itself and may relate directly to the reduced fat absorption. For people with elevated cholesterol or prediabetes, these metabolic shifts could be clinically meaningful.
These benefits do not erase the side-effect profile, but they add context. A drug that causes oily stools and requires vitamin supplementation may still produce a net health benefit for someone at high cardiovascular risk, especially if the alternative is continued weight gain with its own cascade of complications. The GI symptoms are in some sense the price of admission for a mechanism that also improves lipid profiles and modestly lowers blood pressure.
How Orlistat’s Side Effects Compare in the Newer Landscape
With GLP-1 receptor agonists like semaglutide and liraglutide now dominating the weight-loss conversation, orlistat’s side-effect profile lands in a different context than it did when the drug was one of the only options. A systematic review comparing several weight-loss medications noted that both orlistat and GLP-1 drugs cause gastrointestinal discomfort, but the nature differs: orlistat’s effects are centered on fat malabsorption (oily stool, urgency), while GLP-1 drugs tend to cause nausea, vomiting, and early satiety.24PubMed Central. Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review For some people, nausea is more tolerable than oily leakage; for others, the reverse is true. Orlistat also carries no risk of the thyroid tumor concerns flagged in animal studies of GLP-1 drugs, and unlike phentermine, it has no stimulant properties and no potential for dependency.
Orlistat’s biggest practical disadvantage compared to the newer drugs is that it produces much less weight loss, while its GI side effects are arguably more socially disruptive. Oily stool and fecal urgency are not just uncomfortable; they can be embarrassing and unpredictable in ways that nausea is not. This is likely one reason orlistat use has declined sharply as newer options have become available, even though it remains one of the few weight-loss medications sold over the counter.